Erythropoietin receptor signaling mitigates renal dysfunction-associated heart failure by mechanisms unrelated to relief of anemia

Journal of the American College of Cardiology

Volumn 56, Issue 23, 2010, Pages 1949-1958

  Ogino, Atsushi ^a   Takemura, Genzou ^a   Kawasaki, Masanori ^a   Tsujimoto, Akiko ^a   Kanamori, Hiromitsu ^a   Li, Longhu ^a   Goto, Kazuko ^a   Maruyama, Rumi ^a   Kawamura, Itta ^a   Takeyama, Toshiaki ^a   Kawaguchi, Tomonori ^a   Watanabe, Takatomo ^a   Moriguchi, Yoshiyuki ^b   Saito, Hideki ^b   Fujiwara, Takako ^c   Fujiwara, Hisayoshi ^d   Minatoguchi, Shinya ^a  

^a GIFU UNIVERSITY   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^c KYOTO WOMEN'S UNIVERSITY   (Japan)

^d HYOGO PREFECTURAL AMAGASAKI GENERAL MEDICAL CENTER   (Japan)

Author keywords

Anemia; Erythropoietin; Heart failure; Kidney

Indexed keywords

ASIALOERYTHROPOIETIN; CYTOKINE; ERYTHROPOIETIN; HEMOGLOBIN; MITOGEN ACTIVATED PROTEIN KINASE; RECOMBINANT ERYTHROPOIETIN; STAT PROTEIN; TRANSCRIPTION FACTOR GATA 4; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN VENTRICLE DILATATION; CELL INFILTRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DAMAGE; FIBROSIS; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LEUKOCYTE; LIPID PEROXIDATION; MALE; MOUSE; NEPHRECTOMY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMERE; SIGNAL TRANSDUCTION; SURVIVAL;

ANEMIA; ANIMALS; ASIALOGLYCOPROTEINS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEART FAILURE; MALE; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; RECEPTORS, ERYTHROPOIETIN; RENAL INSUFFICIENCY; SIGNAL TRANSDUCTION;

EID: 78649376254     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.04.068     Document Type: Article

References (38)

1. Z.Z. Chong, J.Q. Kang, and K. Maiese Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases Circulation 106 2002 2973 2979
2. G.L. Wright, P. Hanlon, K. Amin, C. Steenbergen, E. Murphy, and M.O. Arcasoy Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury FASEB J 18 2004 1031 1033
3. M.A. Bogoyevitch An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection Cardiovasc Res 63 2004 208 216
4. C.J. Parsa, A. Matsumoto, and J. Kim A novel protective effect of erythropoietin in the infarcted heart J Clin Invest 112 2003 999 1007
5. L. Calvillo, R. Latini, and J. Kajstura Recombinant human erythropoietin protects the myocardium from ischemic-reperfusion injury and promotes beneficial remodeling Proc Natl Acad Sci U S A 100 2003 4802 4806
6. Y. Li, G. Takemura, and H. Okada Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure Cardiovasc Res 71 2006 684 694
7. L. Li, G. Takemura, and Y. Li Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy Circulation 113 2006 535 543
8. R.N. Foley, P.S. Parfrey, and M. Sarnak Cardiovascular disease in chronic renal disease: clinical epidemiology of cardiovascular disease in chronic renal disease Am J Kidney Dis 32 1998 s112 s119
9. J. Silberberg, P.E. Barre, S.S. Prichard, and A.D. Sniderman Impact of left ventricular hypertrophy on survival in end-stage renal disease Kidney Int 36 1989 286 290 (Pubitemid 19202488)
10. B.C. Astor, P. Muntner, A. Levin, J.A. Eustace, and J. Coresh Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (19881994) Arch Intern Med 162 2002 1401 1408 (Pubitemid 34655201)
11. A. Levin Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge Kidney Int Suppl 80 2002 35 38
12. K.D. Pappas, C.D. Gouva, and K.P. Katopodis Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance Cardiovasc Drugs Ther 22 2008 37 44
13. T.B. Drueke, F. Locatelli, N. Clyne CREATE Investigators Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 2006 2071 2084
14. A.K. Singh, L. Szczech, K.L. Tang CHOIR Investigators Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2006 2085 2098
15. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen TREAT Investigators A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 2009 2019 2032
16. T. Quaschning, F. Ruschitzka, and T. Stallmach Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice FASEB J 17 2003 259 261
17. P. Eggena, P. Willsey, and N. Jamgotchian Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems Am J Physiol 261 1991 E642 E646
18. S. Heidenreich, K.H. Rahn, and W. Zidek Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels Kidney Int 39 1991 259 265
19. S.M. Bode-Bger, R.H. Bger, M. Kuhn, J. Radermacher, and J.C. Frlich Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids Kidney Int 50 1996 1255 1261
20. A.E. Raine, and S.D. Roger Effects of erythropoietin on blood pressure Am J Kidney Dis 18 1991 76 83
21. S. Erbayraktar, G. Grasso, and A. Sfacteria Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo Proc Natl Acad Sci U S A 100 2003 6741 6746
22. M.N. Fukuda, H. Sasaki, L. Lopez, and M. Fukuda Survival of recombinant erythropoietin in the circulation: the role of carbohydrates Blood 73 1989 84 89
23. Y. Li, G. Takemura, and H. Okada Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure J Card Fail 13 2007 155 162
24. S. Toyokuni, T. Tanaka, and Y. Hattori Quantitative immunohistochemical determination of 8-hydroxy-2'-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model Lab Invest 76 1997 365 374
25. J.D. Molkentin, D.V. Kalvakolanu, and B.E. Markham Transcription factor GATA-4 regulates cardiac muscle-specific expression of the alpha-myosin heavy-chain gene Mol Cell Biol 14 1994 4947 4957
26. A.M. Murphy, W.R. Thompson, L.F. Peng, and L. Jones II Regulation of the rat cardiac troponin I gene by the transcription factor GATA-4 Biochem J 322 1997 393 401
27. S. Toyokuni, K. Uchida, K. Okamoto, Y. Hattori-Nakakuki, H. Hiai, and E.R. Stadtman Formation of 4-hydroxy-2-nonenal-modified proteins in the renal proximal tubules of rats treated with a renal carcinogen, ferric nitrilotriacetate Proc Natl Acad Sci U S A 91 1994 2616 2620
28. E. Lipsic, B.D. Westenbrink, and P. van der Meer Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit Eur J Heart Fail 10 2008 22 29
29. K. Tyralla, and K. Amann Cardiovascular changes in renal failure Blood Purif 20 2002 462 465 (Pubitemid 35007562)
30. H.N. Sabbah, V.G. Sharov, M. Lesch, and S. Goldstein Progression of heart failure: a role for interstitial fibrosis Mol Cell Biochem 147 1995 29 34
31. P. van der Meer, E. Lipsic, and R.H. Henning Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction J Am Coll Cardiol 46 2005 125 133
32. B.D. Westenbrink, W.P. Ruifrok, and A.A. Voors Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure Cardiovasc Res 87 2010 30 39
33. S.C. Wong, M. Fukuchi, P. Melnyk, I. Rodger, and A. Giaid Induction of cyclooxygenase-2 and activation of nuclear factor-κB in myocardium of patients with congestive heart failure Circulation 98 1998 100 103
34. D.L. Mann Inflammatory mediators and the failing heart: past, present, and the foreseeable future Circ Res 91 2002 988 998
35. D.J. Kennedy, J. Elkareh, and A. Shidyak Partial nephrectomy as a model for uremic cardiomyopathy in the mouse Am J Physiol Renal Physiol 294 2008 F450 F454
36. M. Leist, P. Ghezzi, and G. Grasso Derivatives of erythropoietin that are tissue protective but not erythropoietic Science 305 2004 239 242
37. F. Fiordaliso, S. Chimenti, and L. Staszewsky A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury Proc Natl Acad Sci U S A 102 2005 2046 2051
38. C. Moon, M. Krawczyk, and D. Paik Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties J Pharmacol Exp Ther 316 2006 999 1005